| US 7,491,805 B2 | ||
| Conjugates and compositions for cellular delivery | ||
| Chandra Vargeese, Broomfield, Colo. (US); Peter Haeberli, Berthoud, Colo. (US); Weimin Wang, Superior, Colo. (US); and Tongqian Chen, Longmont, Colo. (US) | ||
| Assigned to Sirna Therapeutics, Inc., San Francisco, Calif. (US) | ||
| Filed on Feb. 13, 2004, as Appl. No. 10/780,447. | ||
| Application 10/780447 is a continuation in part of application No. 10/427160, filed on Apr. 30, 2003. | ||
| Claims priority of provisional application 60/406784, filed on Aug. 29, 2002. | ||
| Claims priority of provisional application 60/386782, filed on Jun. 06, 2002. | ||
| Claims priority of provisional application 60/408378, filed on Sep. 05, 2002. | ||
| Claims priority of provisional application 60/409293, filed on Sep. 09, 2002. | ||
| Claims priority of provisional application 60/440129, filed on Jan. 15, 2003. | ||
| Prior Publication US 2004/0249178 A1, Dec. 09, 2004 | ||
| Int. Cl. A61K 31/7008 (2006.01); A61K 31/7028 (2006.01); C07H 15/04 (2006.01) | ||
| U.S. Cl. 536—17.9 [514/25] | 4 Claims |
1. A compound having Formula 119:
 wherein X comprises a short interfering RNA (siRNA) molecule; W comprises a linker molecule or chemical linkage that can be
present or absent, selected from the group consisting of amide, phosphate, phosphate ester, phosphoramidate, or thiophosphate
ester linkage, each R7 independently comprises an acyl group that can be present or absent, and each n is independently an
integer from about 1 to about 20.
|